We demonstrate that podocalyxin overexpression in PDAC serves as an independent prognostic marker for poor prognosis in patients treated with NAT only if no significant response to NAT was recorded, whereby more than 50% of the viable residual tumor cells appeared in the post-pancreatectomy specimen. The gene discussed is BRD2; the disease is neoplasm.